Latest news
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Sat, 08 Aug 2026 04:39:05 GMTShifting GLP-1 research and development: Lessons learned from the first-generation - drugdiscoverytrends.comdrugdiscoverytrends.com · Fri, 07 Aug 2026 17:18:36 GMTNeurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study - AllSciAllSci · Fri, 07 Aug 2026 16:26:00 GMTNew peer-reviewed clinical study shows Trpti supports the body's natural incretin response - Nutraceutical Business ReviewNutraceutical Business Review · Fri, 07 Aug 2026 10:37:45 GMTEli Lilly's Incretin Performance Supports Long-Term Growth, Truist Says - MoomooMoomoo · Fri, 07 Aug 2026 00:56:31 GMTIncretin-based weight-loss drugs should not be deliberately continued in pregnancy, consensus guidelines state - The Pharmaceutical JournalThe Pharmaceutical Journal · Tue, 04 Aug 2026 19:29:37 GMTStatement Offers Guidance Around Incretin Prescribing - MedscapeMedscape · Thu, 30 Jul 2026 10:51:38 GMT